John Zalcberg, PhD, OAM

home / authors / john-zalcberg,-phd,-oam

Articles

Dr. Zalcberg on the Rationale for Dose Escalation With Ripretinib in Advanced GIST

Dr. Zalcberg on the Rationale for Dose Escalation With Ripretinib in Advanced GIST

John Zalcberg, PhD, OAM
October 21st 2021

John Raymond Zalcberg, PhD, MBBS, discusses the rationale for intra-patient dose escalation with ripretinib, as was examined in the phase 3 INVICTUS trial in patients with advanced gastrointestinal stromal tumors.

Read More

John Raymond Zalcberg, PhD, MBBS

Dr. Zalcberg on the Efficacy of Intra-Patient Dose Escalation With Ripretinib in Advanced GIST

John Zalcberg, PhD, OAM
June 7th 2021

John Raymond Zalcberg, discusses the efficacy of intra-patient dose escalation with ripretinib in patients with advanced gastrointestinal stromal tumors, as demonstrated in an analysis of the phase 3 INVICTUS trial.

Read More

John Zalcberg, ​PhD, OAM

Dr. Zalcberg on the Approval of Avapritinib in GIST

John Zalcberg, PhD, OAM
November 12th 2020

John Zalcberg, ​PhD, OAM, discusses the approval of avapritinib in gastrointestinal stromal tumor.

Read More

John Zalcberg, ​PhD, OAM

Dr. Zalcberg on the Role of Ripretinib in Advanced GIST

John Zalcberg, PhD, OAM
November 10th 2020

John Zalcberg, ​PhD, OAM, discusses the role of Gastrointestinal Cancer in advanced gastrointestinal stromal tumor​.

Read More

Dr. Zalcberg on the Management of Patients With GIST

Dr. Zalcberg on the Management of Patients With GIST

John Zalcberg, PhD, OAM
October 1st 2020

John Zalcberg, ​PhD, OAM, discusses the management of patients with gastrointestinal stromal tumor​.

Read More

Dr. Zalcberg on Updated Results from the Phase 3 INVICTUS Study in Advanced GIST

Dr. Zalcberg on Updated Results from the Phase 3 INVICTUS Study in Advanced GIST

John Zalcberg, PhD, OAM
September 20th 2020

John Zalcberg, ​PhD, OAM, discusses updated results from the phase 3 INVICTUS trial in advanced gastrointestinal stromal tumor.

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need